Overexpression of CARM1 in breast cancer is correlated with poorly characterized clinicopathologic parameters and molecular subtypes

Table 1 Correlation between nuclear CARM1 expression and the clinicopathologic characteristics of breast cancer patients

Clinicopathologic characteristics	n	Nuclear CARM1 expression		P *
Clinicopathologic characteristics	n	Negative or low expression (IHC score < 80)	High or over expression (IHC score f ≥ 80)	P *
Age(y)
≤40	53	16 (30.2)	37 (69.8)	0.002
>40	194	105 (54.1)	89 (45.9)
Tumor size
≤2 cm	125	65 (52.0)	60 (48.0)	0.338
>2 cm	122	56 (45.9)	66 (54.1)
Tumor number
1	234	121 (51.7)	113 (48.3)	<0.001
≥2	13	0 (0)	13 (100.0)
Grade
I&II	181	96 (53.0)	85 (47.0)	0.035
III	66	25 (37.9)	41 (62.1)
Lymph node metastasis
N0	127	56 (44.1)	71 (55.9)	0.113
N1, N2,N3	120	65 (54.2)	55 (45.8)
TNM stage
I	74	36 (48.6)	38 (51.4)	0.886
II	111	53 (47.7)	58 (52.3)
III	62	32 (51.6)	30 (48.4)
ER
negative	90	35 (38.9)	55 (61.1)	0.016
positive	157	86 (54.8)	71 (45.2)
PR
negative	136	56 (41.2)	80 (58.8)	0.007
positive	111	65 (58.6)	46 (41.4)
HER2
negative	206	107 (51.9)	99 (48.1)	0.037
positive	41	14 (34.1)	27 (65.9)
Expression of Ki67
low (≤10%)	55	35 (63.6)	20 (36.4)	0.014
high (>10%)	192	86 (44.8)	106 (55.2)
Expression of P53
low	95	57 (60.0)	38 (40.0)	0.006
high	152	64 (42.1)	88 (57.9)

* P value is the result of x² test in the same factor, and < 0.05 is considered statistically significant.

ISSN: 1746-1596